Skip to main content
. 2018 Mar 19;12(7):E349–E356. doi: 10.5489/cuaj.4898

Table 5.

Summary of AEs by treatment condition in the phase 1 PK study

Type of event Asymptomatic state Symptomatic state Symptomatic treated state
n 18 15 17
Any AE, n (%) 3 (16.7) 4 (26.7) 5 (29.4)
TEAE, n (%) 3 (16.7) 4 (26.7) 5 (29.4)
AE by intensity, n
 Mild 3 4 4
 Moderate 0 0 2

AE: adverse event; E: number of reported AEs; PK: pharmacokinetic; TEAE: treatmentemergent adverse event.